NGN Capital is a venture capital firm specializing in investments in the US and European healthcare sector.
Business Model:
Revenue: $5.8M
Employees: 2-10
Address: 369 Lexington Ave
City: New York
State: NY
Zip: 10017
Country: US
NGN Capital is a venture capital firm specializing in investments in the US and European healthcare sector. The fund focuses specifically on investments in the healthcare, pharmaceutical, and biotech sectors including drug products, medical devices, diagnostics, and healthcare services.
Contact Phone:
+12129720077
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
7/2017 | Exosome Diagnostics | Series C | 0 |
8/2005 | Sightline Technologies | Series D | 0 |
3/2006 | EKOS Corporation | Series C | 0 |
1/2007 | Tigris Pharmaceuticals | Series B | 16M |
7/2010 | Artisan Pharma | Series C | 0 |
3/2010 | Valtech Cardio | Series B | 17.8M |
11/2005 | Javelin Pharmaceuticals | Private Equity Round | 32M |
2/2005 | Jerini | Venture Round | 20.2M |
10/2006 | Santhera Pharmaceuticals | Series C | 0 |
1/2016 | Exosome Diagnostics | Series B | 0 |
3/2014 | Exosome Diagnostics | Series B | 0 |
7/2007 | BeneChill | Series B | 3.5M |
12/2004 | Santhera Pharmaceuticals | Series A | 0 |
4/2009 | Aerovance | Venture Round | 38M |
11/2013 | Endosense | Series C | 41.2M |
3/2010 | Artisan Pharma | Series B | 22M |
9/2006 | Artisan Pharma | Series A | 39M |
4/2009 | Small Bone Innovations | Series D | 0 |
7/2012 | Cerapedics | Series C | 0 |
5/2010 | Noxxon Pharma | Series D | 40.7M |
11/2012 | Endosense | Series C | 40.3M |
3/2007 | Aerovance | Series C | 60M |
9/2015 | Exosome Diagnostics | Series B | 0 |
2/2005 | EKOS Corporation | Series B | 0 |
3/2007 | Nitec Pharma AG | Series B | 26M |
12/2010 | Small Bone Innovations | Series F | 0 |
1/2008 | Small Bone Innovations | Series C | 0 |
12/2005 | Small Bone Innovations | Series B | 0 |
1/2009 | Vivaldi Biosciences | Series A | 23M |
4/2009 | Cerapedics | Series B | 15M |
8/2004 | Aerovance | Series B | 32M |
9/2009 | BeneChill | Series C | 13.5M |
12/2005 | Santhera Pharmaceuticals | Series B | 0 |
10/2008 | Micromet | Post-IPO Equity | 0 |
1/2014 | PIN Pharma | Series A | 6.8M |
5/2010 | Exosome Diagnostics | Series A | 20M |
10/2005 | OptiScan Biomedical | Venture Round | 36M |
5/2008 | ACT Biotech | Series A | 6.6M |
7/2017 | Exosome Diagnostics | Series C | 0 |
1/2016 | Exosome Diagnostics | Series B | 0 |
9/2015 | Exosome Diagnostics | Series B | 0 |
3/2014 | Exosome Diagnostics | Series B | 0 |
1/2014 | PIN Pharma | Series A | 0 |
11/2013 | Endosense | Series C | 0 |
11/2012 | Endosense | Series C | 0 |
7/2012 | Cerapedics | Series C | 0 |
12/2010 | Small Bone Innovations | Series F | 0 |
7/2010 | Artisan Pharma | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|